Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine (DACOGEN) followed by cytarabine in children with relapsed or refractory acute myeloid leukemia
NL-OMON40223Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of decitabine and cytarabine in acute myeloid leukemia (AML), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose-limiting toxicity of cytarabine, Complete response plus complete response with incomplete blood count recovery rate and 1 more. Started Sep 2015; status: recruiting.
02
Drugs
decitabinecytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON40223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40223.